期刊
METABOLISM-CLINICAL AND EXPERIMENTAL
卷 145, 期 -, 页码 -出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.metabol.2023.155607
关键词
Fatty liver; NAFLD; MAFLD; NASH; MASH; Cirrhosis; Hepatocytes; Hepatic stellate cells; Lipogenesis; Insulin resistance; Insulin clearance
Over 65% of obese individuals suffer from metabolic-associated fatty liver disease (MAFLD), which can lead to various conditions such as steatohepatitis, fibrosis, cirrhosis, or liver cancer. This review discusses the role of insulin signaling, hepatic insulin resistance, and reduced insulin clearance in the development of MAFLD, emphasizing the potential use of insulin sensitizers as a treatment approach. Additionally, the review explores the involvement of the insulin receptor in hepatocytes and hepatic stellate cells and its implications in metabolic and end-stage liver diseases. It also discusses the possibility of using insulin sensitizers to manage late-stage liver diseases based on recent research findings.
Over 65 % of people with obesity display the metabolic-associated fatty liver disease (MAFLD), which can manifest as steatohepatitis, fibrosis, cirrhosis, or liver cancer. The development and progression of MAFLD involve hepatic insulin resistance and reduced insulin clearance. This review discusses the relationships between altered insulin signaling, hepatic insulin resistance, and reduced insulin clearance in the development of MAFLD and how this provides the impetus for exploring the use of insulin sensitizers to curb this disease. The review also explores the role of the insulin receptor in hepatocytes and hepatic stellate cells and how it signals in metabolic and end-stage liver diseases. Finally, we discuss new research findings that indicate that advanced hepatic dis-eases may be an insulin-sensitive state in the liver and deliberate whether insulin sensitizers should be used to manage late-stage liver diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据